基因1b型丙型肝炎病毒NS5A区变异及其与聚乙二醇干扰素α-2a联合利巴韦林治疗应答的相关性  

Mutations in the NS5A region of hepatitis C virus genotype lb and correlation with response to pegylated interferon alpha-2α and ribavirin combination therapy

作　　者：傅涓涓[1] 孔玮晶[1] 蒋栋[2] 魏来[2] 潘修成[1] 

机构地区：[1]徐州医学院附属医院感染性疾病科,徐州221002 [2]北京大学人民医院肝病研究所

出　　处：《中华实验和临床病毒学杂志》2013年第6期458-460,共3页Chinese Journal of Experimental and Clinical Virology

摘　　要：目的探讨基因1b型慢性丙型肝炎患者NS5A区基因变异与聚乙二醇干扰素α-2a（PEG—IFNα-2a）联合利巴韦林（RBV）抗病毒治疗疗效的关系。方法回顾性选择15例应用PEG—IFNα-2a／RBV抗病毒治疗的基因1b型慢性丙型肝炎患者，其中7例为快速应答（RVR），8例为无应答（NR），应用RT—PCR法扩增NS5A全长片段，用克隆测序方法进行核苷酸和氨基酸序列测定。结果没有发现与治疗应答相关的单个氨基酸或基序变异，RVR组和NR组在NS5A、ISDR、PKRBD和IRRDR区的氨基酸突变数目差别均无统计学意义，RVR组在V3区（aa2356～2379）的氨基酸突变数目高于NR组（分别为5．3±0.5和3．4±0．6，P=0．03）。结论V3区的氨基酸突变数目与PEG—IFNα-2a联合RBV抗病毒疗效可能相关。Objective To investigate whether the variability in the NS5A region among patients with hepatitis C virus（HCV） genotype lb affect the response to pegylated interferon alpha-2a（PEG-IFNα-2a） and ribavirin（RBV） combination therapy. Methods We retrospectively analyzed 15 patients （7 with rapid virological response and 8 non-response to therapy） with chronic HCV genotype-lb infection treated with PEG-IFNct-2a plus RBV. The entire NS5A region was amplified by reverse transcription （RT） -PCR followed by cloned sequenced. Results No single amino acid and motif substitution were associated with different responses to therapy in any of the NS5A regions. No significant differences were found in the number of mutations in the full-length NS5A, ISDR, PKRBD, and IRRDR. The number of mutations in the V3 region （aa 2356-2379）was higher in patients with rapid virological response than in patients with non-response （5.3 ±0.5 and 3.4 ±0.6 respectively, P = 0. 03 ）. Conclusion The number of amino acid mutations in the V3 region was correlated with RVR to PEG-IFNα-2a plus RBV therapy in HCV-lb patients.

关 键 词：肝炎 丙型 干扰素A 聚乙烯二醇类 利巴韦林 

分 类 号：R512.63[医药卫生—内科学]